- Home
- FLYE vs AYTU Comparison
FLYE vs AYTU Comparison
Compare FLYE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- AYTU
- Stock Information
- Founded
- FLYE 2018
- AYTU N/A
- Country
- FLYE United States
- AYTU United States
- Employees
- FLYE N/A
- AYTU N/A
- Industry
- FLYE Aerospace
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- AYTU Health Care
- Exchange
- FLYE Nasdaq
- AYTU Nasdaq
- Market Cap
- FLYE 91.6M
- AYTU 18.8M
- IPO Year
- FLYE 2024
- AYTU N/A
- Fundamental
- Price
- FLYE $0.66
- AYTU $2.36
- Analyst Decision
- FLYE
- AYTU Strong Buy
- Analyst Count
- FLYE 0
- AYTU 3
- Target Price
- FLYE N/A
- AYTU $9.17
- AVG Volume (30 Days)
- FLYE 642.8K
- AYTU 414.1K
- Earning Date
- FLYE 11-18-2025
- AYTU 11-12-2025
- Dividend Yield
- FLYE N/A
- AYTU N/A
- EPS Growth
- FLYE N/A
- AYTU N/A
- EPS
- FLYE N/A
- AYTU N/A
- Revenue
- FLYE $22,881,935.00
- AYTU $66,382,000.00
- Revenue This Year
- FLYE N/A
- AYTU N/A
- Revenue Next Year
- FLYE N/A
- AYTU $19.03
- P/E Ratio
- FLYE N/A
- AYTU N/A
- Revenue Growth
- FLYE N/A
- AYTU 1.84
- 52 Week Low
- FLYE $0.51
- AYTU $0.95
- 52 Week High
- FLYE $8.30
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- FLYE 34.92
- AYTU 54.93
- Support Level
- FLYE $0.65
- AYTU $1.65
- Resistance Level
- FLYE $0.72
- AYTU $2.58
- Average True Range (ATR)
- FLYE 0.05
- AYTU 0.17
- MACD
- FLYE 0.07
- AYTU 0.05
- Stochastic Oscillator
- FLYE 6.42
- AYTU 74.19
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.